Millipore Sigma Vibrant Logo

476275 Myricetin - CAS 529-44-2 - Calbiochem

A cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties.

Myricetin - CAS 529-44-2 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: 3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II

View Products on Sigmaaldrich.com
476275
查看价格及供货情况

概述

Replacement Information

重要规格表

CAS #Empirical Formula
529-44-2C₁₅H₁₀O₈

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
476275-25MGCN
正在查询供货情况......
—
目前缺货 目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余：另行通知
      其余：另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      		 塑胶安瓿;塑胶针药瓶 25 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      Catalogue Number476275
      Brand Family Calbiochem®
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      References
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Product Information
      CAS number529-44-2
      FormYellowish brown solid
      Hill FormulaC₁₅H₁₀O₈
      Chemical formulaC₁₅H₁₀O₈
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      476275-25MGCN 04055977184471

      Documentation

      Myricetin - CAS 529-44-2 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      Myricetin - CAS 529-44-2 - Calbiochem 分析证书

      标题批号
      476275

      参考

      参考信息概述
      Lee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-November-2008 JSW
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      DescriptionA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      FormYellowish brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number529-44-2
      Chemical formulaC₁₅H₁₀O₈
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.